Stockscreener 앱 받기
1.09
0.91%
-0.01
전일 마감가:
$1.10
열려 있는:
$1.07
하루 거래량:
21,358
Relative Volume:
0.01
시가총액:
$9.47M
수익:
$1.52M
순이익/손실:
$-13.97M
주가수익비율:
-0.3574
EPS:
-3.05
순현금흐름:
$-13.29M
1주 성능:
+2.83%
1개월 성능:
-18.66%
6개월 성능:
+55.71%
1년 성능:
-39.78%
1일 변동 폭
$1.0501
$1.1083
1주일 범위
$1.01
$1.2336
52주 변동 폭
$0.55
$3.06
Predictive Oncology Inc Stock (POAI) Company Profile
명칭
Predictive Oncology Inc
전화
412-432-1500
주소
91 43RD STREET, PITTSBURGH, MN
POAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
POAI
Predictive Oncology Inc
|
1.09 | 9.47M | 1.52M | -13.97M | -13.29M | -3.05 |
|
ISRG
Intuitive Surgical Inc
|
534.15 | 184.23B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.74 | 48.46B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
98.04 | 47.15B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
240.78 | 35.24B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
82.09 | 16.39B | 3.90B | 392.30M | 288.10M | 1.95 |
Predictive Oncology Inc Stock (POAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 개시 | H.C. Wainwright | Buy |
Predictive Oncology Inc 주식(POAI)의 최신 뉴스
Head-To-Head Review: Pathfinder Cell Therapy (OTCMKTS:PFND) versus Predictive Oncology (NASDAQ:POAI) - Defense World
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire) - Aktiellt
Predictive Oncology (POAI) Advances in Drug Repurposing with AI Innovations | POAI Stock News - GuruFocus
Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs - GlobeNewswire
Revolutionary AI Platform Revives Abandoned Cancer Drugs with Stunning Results - Stock Titan
Predictive Oncology Ends Merger Talks with Renovaro - TipRanks
Renovaro says Predictive Oncology terminates merger transaction - MSN
Health Care Stocks Tumble On Multiple Fronts - Finimize
Renovaro Biosciences faces merger setback with Predictive Oncology By Investing.com - Investing.com Canada
Renovaro Biosciences faces merger setback with Predictive Oncology - Investing.com India
Renovaro Says Predictive Oncology Terminates Merger Transaction With Co - marketscreener.com
Renovaro BioSciences (RENB) Challenges Merger Termination - GuruFocus
Renovaro Biosciences Announces Breach Of Agreement By Predictive Oncology, Legal Action Pending - Nasdaq
Renovaro Says Predictive Oncology Terminates Merger Deal; Shares Fall - MarketScreener
Renovaro Provides Update to Definitive Agreement with Predictive Oncology - GlobeNewswire
Merger Crisis: Renovaro Threatens Legal Action After Predictive Oncology Backs Out - Stock Titan
Predictive Oncology Reports 2024 Financial Results and Merger Plans - TipRanks
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology pushing forward with Renovaro merger despite $10.8M loss in 2024 - The Business Journals
Predictive Oncology Advances AI Merger Plans Despite $10.8M Loss: Key Strategic Moves Revealed - Stock Titan
Predictive Oncology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Predictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer Research - Insider Monkey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Predictive Oncology developed predictive models from 21 compounds from NPDC - TipRanks
Predictive Oncology Successfully Develops Predictive Models - GlobeNewswire
Predictive Oncology (POAI) Stock Surges Following Major Drug Discovery Breakthrough - Stocks Telegraph
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary - The Manila Times
Predictive Oncology Develops Advanced Predictive Models for Natural Compounds in Cancer Drug Discovery - Nasdaq
Milestone Merger Payment with Predictive Oncology to Advance AI - newschannelnebraska.com
Predictive Oncology Sells Skyline Medical Assets To DeRoyal Industries - Nasdaq
Predictive Oncology Sells Skyline Medical Assets to DeRoyal Industries - citybiz
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries to Focus on AI-Driven Drug Discovery - Nasdaq
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries - GlobeNewswire
Strategic Pivot: Predictive Oncology Divests Medical Assets for AI-Powered Future - Stock Titan
Predictive Oncology (POAI) Expected to Announce Earnings on Thursday - Defense World
Predictive Oncology to launch ChemoFx assay in Europe - MSN
Predictive Oncology receives financing from Renovaro Biosciences - Pennsylvania Business Report -
Renovaro (RENB) and Predictive Oncology Partner for AI-Driven Drug Discovery: What’s Next for Cancer and HIV Treatments? - Insider Monkey
Renovaro provides financing to Predictive Oncology as both move to finalize definitive merger agreement - The Business Journals
MarketsMedicine Hat News - Financial Content
Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB) - The Globe and Mail
Milestone Merger Payment made with Predictive Oncology - openPR
Renovaro Completes First Milestone Payment To Finalize Definitive Agreement With Predictive Oncology - Marketscreener.com
Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology - GlobeNewswire
Predictive Oncology Moves To Finalize Definitive Merger Agreement With Renovaro Biosciences - Marketscreener.com
Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences - The Manila Times
Renovaro completes first milestone payment for Predictive Oncology deal - TipRanks
Renovaro Biosciences Advances Financing for AI-Driven Integration and Strategic Expansion in Oncology through Acquisition of Predictive Oncology - Nasdaq
Can Renovaro's AI Oncology Merger Unlock Value From 150,000+ Tumor Samples? - StockTitan
Predictive Oncology Inc (POAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
0.71%
자본화:
|
볼륨(24시간):